Keywords
Ultraviolet radiation
Quality of life
Pruritus
IgE
Antinuclear antibodies
Rheumatoid factor
Omalizumab
Antihistamines
How to Cite
Abstract
Background: Solar urticaria is a rare condition induced by exposure to ultraviolet radiation. Although it typically resolves spontaneously, like other dermatoses, it often affects patients’ quality of life. We report the case of a patient with solar urticaria successfully treated with omalizumab.
Case Report: A 36-year-old female patient with a history of allergies presented with pruritic wheals in sun-exposed areas for four years. Despite unremarkable physical findings, erythematous-edematous plaques were observed. Serum IgE levels were elevated (507 IU/ml), and antinuclear antibodies and rheumatoid factor were negative. Initial treatment with levocetirizine (up to 20 mg/day) and photoprotection failed, with a UCT score of 10. Omalizumab (300 mg/4 weeks) was added, achieving complete control of the condition (UCT score 16) after five months, allowing for a reduction in the dose and dosing interval. However, episodes during the spring season (UCT score 6) necessitated reintroducing the initial dose to regain full disease control.
Conclusion: Omalizumab is a second-line anti-IgE monoclonal antibody for the off-label treatment of patients who do not respond to systemic antihistamines.
Keywords: Solar urticaria; Ultraviolet radiation; Quality of life; Pruritus; IgE; Antinuclear antibodies; Rheumatoid factor; Omalizumab; Antihistamines.
References
1. García-Díez I, Curto-Barredo L, Weller K, Pujol R, et al. Adaptación Transcultural Del Cuestionario Urticaria Control Test Del Alemán al Castellano. Actas Dermo-Sifiliograficas 2015; 106 (9): 746-52.
2. Spertino J, Curto-Barredo L, Rozas-Muñoz E, Figueras-Nart I, et al. Algoritmo de Tratamiento Con Omalizumab En Urticaria Crónica Espontánea.” Actas Dermo-Sifiliograficas 2018; 109 (9): 771-76.
3. McSweeney SM, Sarkany R, Fassihi H, Tziotzios C, et al. Pathogenesis of Solar Urticaria: Classic Perspectives and Emerging Concepts. Exp Dermatol 2022; 31 (4): 586-93.
4. Steven G, Elsner P. Solar Urticaria. J Der Deutschen Dermatol Gesellschaft 2015; 13 (12): 125053.
5. Torsten Z, Abdul Latiff AH, Abuzakouk M, Aquilina S, et al. The International EAACI/GA2LEN/EuroGuiDerm/APAAACI Guideline for the Definition, Classification, Diagnosis, and Management of Urticaria. Allergy 2022; 77 (3): 734-66.
6. Folci M, Ramponi G, Brunetta E. A Comprehensive Approach to Urticaria: From Clinical Presentation to Modern Biological Treatments through Pathogenesis. Adv Exp Med Biol 2021; 1326: 111-37.
7. Antia C, Baquerizo K, Korman A, Alikhan A, et al. Urticaria: A Comprehensive Review: Treatment of Chronic Urticaria, Special Populations, and Disease Outcomes. J Am Acad Dermatol 2018; 79 (4): 617-33.
8. Chicharro P, Rodríguez-Jiménez P, Capusan TM, Herrero-Moyano M, et al. Inducción de fototolerancia con ultravioleta B de banda estrecha en urticaria solar. Actas Dermo-Sifiliográficas 2019; 109, (10): 888-892.
9. Hayashi N, Tsukamoto Y, Sallas WM, Lowe PJ. A mechanism-based binding model for the population pharmacokinetics and pharmacodynamics of omalizumab. Br J Clin Pharmacol. 2007; 63 (5): 548-61.
10. Jia HX, He YL. Efficacy and Safety of Omalizumab for Chronic Spontaneous Urticaria: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Am J Ther 2020; 27(5): 455-467.
11. Casanova-Esquembre A, Lorca-Spröhnle J, Peñuelas-Leal R, Pérez-Ferriols A. Solar Urticaria and Omalizumab: A Retrospective Case-Control Study and Follow-Up. Actas Dermo-Sifiliograficas 2024; 115 (9): 931-32.
12. Morgado-Carrasco D, Giácaman-Von der Weth M, Fustá-Novell X, Podlipnik S, et al. Clinical response and long-term follow-up of 20 patients with refractory solar urticaria under treatment with omalizumab. J Am Acad Dermatol 2023; 88 (5): 1110-1111.
13. Baliu-Piqué C, Aguilera Peiró P. Three cases of solar urticaria successfully treated with omalizumab. J Eur Acad Dermatol Venereol 2016; 30 (4): 704-6.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright (c) 2025 Revista Alergia México